Balloon pulmonary angioplasty (BPA) is now a critical part of treatment for selected patients with chronic thromboembolic pulmonary hypertension, including those who are not surgical candidates, have surgically inaccessible distal disease or have symptomatic residual disease after pulmonary thromboendarterectomy, a new review concludes.